Oncology and Hematology
Oncology and Hematology Clinical Practice
Stay current with Oncology and Hematology education that fits how you practice. ReachMD offers practical, on-demand clinical content for oncologists, hematologists, oncology nurses, pharmacists, fellows, APPs, and the full cancer care team. Explore expert discussions, case-based programs, CME/CE opportunities, industry features, and news across solid tumors, hematologic malignancies, biomarker-driven care, immunotherapy, targeted therapy, supportive care, and more.
Use this page to find relevant oncology and hematology content fast. Browse Project Oncology episodes, jump into CME/CE activities, review expert perspectives, or explore timely updates on evolving treatment strategies and standards of care. New content is added regularly, so you can stay current with emerging evidence, guideline updates, and multidisciplinary approaches to cancer care on your schedule.
Start with the latest programs below or browse by content type to find the Oncology and Hematology education most relevant to your practice.
31-45 of 298
Navigating Treatment Sequencing After Frontline Treatment Failure in CLL
CME/CENavigating Treatment Sequencing After Frontline Treatment Failure in CLL
Jennifer R. Brown, MD, PhD
William Mencia, MD, FACEHP
William Wierda, MD, PhD
Matthew S. Davids, MD, MMSc
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
CME/CEAdvancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
Kevin J Harrington, PhD, FRCP, FRCR, FRSB
Cristina Rodriguez, MD
Progress in Breast Cancer Care: Translating SABCS Data Into Practice
CME/CEProgress in Breast Cancer Care: Translating SABCS Data Into Practice
Charles E. Geyer Jr., MD, FACP
Komal Jhaveri, MD, FACP
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
CME/CEFrom Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
María-Victoria Mateos, MD, PhD
Luciano Costa, M.D., Ph.D.
Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
MinuteCE®Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
Kathryn Arbour
Eileen M. O'Reilly, MD
- advertisement
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors
MinuteCE®Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors
Eileen M. O'Reilly, MD
- MinuteCE®
The New Era of RAS Targeting: Mechanisms, Evidence, and Clinical Integration of ON-State Inhibitors
Kathryn Arbour
Eileen M. O'Reilly, MD
Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
MinuteCE®Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
Eileen M. O'Reilly, MD
Kathryn Arbour
Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
MinuteCE®Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
Kathryn Arbour
Eileen M. O'Reilly, MD
Kathryn Arbour
Eileen M. O'Reilly, MD
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
MinuteCE®NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
Kathryn Arbour
- advertisement
RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
MinuteCE®RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
Kathryn Arbour
Eileen M. O'Reilly, MD
Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
MinuteCE®Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
Kathryn Arbour
Eileen M. O'Reilly, MD
Frontline Insights: Emerging Therapeutic Strategies in HNSCC
CME/CEFrontline Insights: Emerging Therapeutic Strategies in HNSCC
Kevin J Harrington, PhD, FRCP, FRCR, FRSB
Christophe Le Tourneau, MD, PhD
